MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574276 | Name: Febuxostat acyl glucuronide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Febuxostat acyl glucuronide is a metabolite of the xanthine oxidoreductase inhibitor febuxostat. Febuxostat acyl glucuronide is formed via glucuronidation of febuxostat by uridine diphosphate-glucuronosyltransferases (UGTs).

Chemical Structure

Febuxostat acyl glucuronide
Febuxostat acyl glucuronide
CAS#1351692-92-6

Theoretical Analysis

MedKoo Cat#: 574276

Name: Febuxostat acyl glucuronide

CAS#: 1351692-92-6

Chemical Formula: C22H24N2O9S

Exact Mass: 492.1203

Molecular Weight: 492.50

Elemental Analysis: C, 53.65; H, 4.91; N, 5.69; O, 29.24; S, 6.51

Price and Availability

Size Price Availability Quantity
1mg USD 350.00 Back order
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Febuxostat acyl glucuronide; FebuxostatAcyl-beta-D-glucuronide; Febuxostat Acyl-b-D-glucuronide
IUPAC/Chemical Name
(2S,3S,4S,5R,6S)-6-((2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carbonyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
InChi Key
ZRXRMGPMLDOOKN-FVMGUFKOSA-N
InChi Code
InChI=1S/C22H24N2O9S/c1-9(2)8-31-13-5-4-11(6-12(13)7-23)19-24-10(3)18(34-19)21(30)33-22-16(27)14(25)15(26)17(32-22)20(28)29/h4-6,9,14-17,22,25-27H,8H2,1-3H3,(H,28,29)/t14-,15-,16+,17-,22-/m0/s1
SMILES Code
CC(C)COC1=C(C#N)C=C(C2=NC(C)=C(C(O[C@@H]3O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]3O)=O)S2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
A metabolite of febuxostat.
In vitro activity:
The gene expression level of iNOS was significantly increased by stimulation with IL-18 but greatly suppressed by the introduction of Febuxostat (Figure 4A). The increased release of NO induced by stimulation with IL-18 was significantly inhibited in the presence of Febuxostat (Figure 4B). Reference: Am J Transl Res. 2021; 13(3): 979–987. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014396/
In vivo activity:
The gingival expression of TNF-α, IL-1β, 4-HNE, and 8-OHdG was up-regulated in rats with periodontitis. Febuxostat significantly reduced alveolar bone loss, proinflammatory cytokine levels, and oxidative stress. Reference: Pharmacology. 2021;106(5-6):294-304. https://pubmed.ncbi.nlm.nih.gov/33735887/

Preparing Stock Solutions

The following data is based on the product molecular weight 492.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Geng Q, Zhang H, Cui Y, Wei Q, Wang S. Febuxostat mitigates IL-18-induced inflammatory response and reduction of extracellular matrix gene. Am J Transl Res. 2021 Mar 15;13(3):979-987. PMID: 33841634; PMCID: PMC8014396. 2. Hao J, Zhang W, Tong R, Huang Z. Febuxostat Prevents the Cytotoxicity of Propofol in Brain Endothelial Cells. ACS Omega. 2021 Feb 15;6(8):5471-5478. doi: 10.1021/acsomega.0c05708. PMID: 33681587; PMCID: PMC7931401. 3. Tsukamoto T, Tsujii M, Odake K, Iino T, Nakamura T, Matsumine A, Sudo A. Febuxostat reduces muscle wasting in tumor-bearing mice with LM8 osteosarcoma cells via inhibition of reactive oxygen species generation. Free Radic Res. 2021 Jul 19:1-11. doi: 10.1080/10715762.2021.1947502. Epub ahead of print. PMID: 34278932. 4. Nessa N, Kobara M, Toba H, Adachi T, Yamamoto T, Kanamura N, Pezzotti G, Nakata T. Febuxostat Attenuates the Progression of Periodontitis in Rats. Pharmacology. 2021;106(5-6):294-304. doi: 10.1159/000513034. Epub 2021 Mar 18. PMID: 33735887.
In vitro protocol:
1. Geng Q, Zhang H, Cui Y, Wei Q, Wang S. Febuxostat mitigates IL-18-induced inflammatory response and reduction of extracellular matrix gene. Am J Transl Res. 2021 Mar 15;13(3):979-987. PMID: 33841634; PMCID: PMC8014396. 2. Hao J, Zhang W, Tong R, Huang Z. Febuxostat Prevents the Cytotoxicity of Propofol in Brain Endothelial Cells. ACS Omega. 2021 Feb 15;6(8):5471-5478. doi: 10.1021/acsomega.0c05708. PMID: 33681587; PMCID: PMC7931401.
In vivo protocol:
1. Tsukamoto T, Tsujii M, Odake K, Iino T, Nakamura T, Matsumine A, Sudo A. Febuxostat reduces muscle wasting in tumor-bearing mice with LM8 osteosarcoma cells via inhibition of reactive oxygen species generation. Free Radic Res. 2021 Jul 19:1-11. doi: 10.1080/10715762.2021.1947502. Epub ahead of print. PMID: 34278932. 2. Nessa N, Kobara M, Toba H, Adachi T, Yamamoto T, Kanamura N, Pezzotti G, Nakata T. Febuxostat Attenuates the Progression of Periodontitis in Rats. Pharmacology. 2021;106(5-6):294-304. doi: 10.1159/000513034. Epub 2021 Mar 18. PMID: 33735887.
1. Grabowski, B.A., Khosravan, R., Vernillet, L., et al. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J. Clin. Pharmacol. 51(2), 189-201 (2011). 2. Kamel, B., Graham, G.G., Williams, K.M., et al. Clinical pharmacokinetics and pharmacodynamics of febuxostat. Clin. Pharmacokinet. 56(5), 459-475 (2017).